Cargando…

Prognostic Accuracy of Immunologic and Metabolic Markers for Type 1 Diabetes in a High-Risk Population: Receiver operating characteristic analysis

OBJECTIVE: To establish and compare the prognostic accuracy of immunologic and metabolic markers in predicting onset of type 1 diabetes in those with high risk in a prospective study. RESEARCH DESIGN AND METHODS: A total of 339 subjects from the Diabetes Prevention Trial–Type 1 (DPT-1) parenteral st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Ping, Beam, Craig A., Cuthbertson, David, Sosenko, Jay M., Skyler, Jay S., Krischer, Jeffrey P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2012
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3447832/ https://www.ncbi.nlm.nih.gov/pubmed/22787174 http://dx.doi.org/10.2337/dc12-0183

Ejemplares similares

Prognostic Performance of Metabolic Indexes in Predicting Onset of Type 1 Diabetes
por: Xu, Ping, et al.
Publicado: (2010)

Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for Improving the Accuracy of the Risk Classification of Type 1 Diabetes
por: Sosenko, Jay M., et al.
Publicado: (2014)

Validation of the Diabetes Prevention Trial–Type 1 Risk Score in the TrialNet Natural History Study
por: Sosenko, Jay M., et al.
Publicado: (2011)

The Application of the Diabetes Prevention Trial–Type 1 Risk Score for Identifying a Preclinical State of Type 1 Diabetes
por: Sosenko, Jay M., et al.
Publicado: (2012)

Erratum. Validation of the Diabetes Prevention Trial–Type 1 Risk Score in the TrialNet Natural History Study. Diabetes Care 2011;34:1785–1787
por: Sosenko, Jay M., et al.
Publicado: (2018)

Glucose and C-Peptide Changes in the Perionset Period of Type 1 Diabetes in the Diabetes Prevention Trial–Type 1
por: Sosenko, Jay M., et al.
Publicado: (2008)

Development of Autoantibodies in the TrialNet Natural History Study
por: Vehik, Kendra, et al.
Publicado: (2011)

Trends of Earlier and Later Responses of C-peptide to Oral Glucose Challenges With Progression to Type 1 Diabetes in Diabetes Prevention Trial–Type 1 Participants
por: Sosenko, Jay M., et al.
Publicado: (2010)

A Longitudinal Study of GAD65 and ICA512 Autoantibodies During the Progression to Type 1 Diabetes in Diabetes Prevention Trial–Type 1 (DPT-1) Participants
por: Sosenko, Jay M., et al.
Publicado: (2011)

The Prediction of Type 1 Diabetes by Multiple Autoantibody Levels and Their Incorporation Into an Autoantibody Risk Score in Relatives of Type 1 Diabetic Patients
por: Sosenko, Jay M., et al.
Publicado: (2013)

Acceleration of the Loss of the First-Phase Insulin Response During the Progression to Type 1 Diabetes in Diabetes Prevention Trial–Type 1 Participants
por: Sosenko, Jay M., et al.
Publicado: (2013)

Pancreatic Islet Autoantibodies as Predictors of Type 1 Diabetes in the Diabetes Prevention Trial–Type 1
por: Orban, Tihamer, et al.
Publicado: (2009)

Incident Dysglycemia and Progression to Type 1 Diabetes Among Participants in the Diabetes Prevention Trial–Type 1
por: Sosenko, Jay M., et al.
Publicado: (2009)

Glucose Excursions Between States of Glycemia With Progression to Type 1 Diabetes in the Diabetes Prevention Trial–Type 1 (DPT-1)
por: Sosenko, Jay M., et al.
Publicado: (2010)

Zinc Transporter-8 Autoantibodies Improve Prediction of Type 1 Diabetes in Relatives Positive for the Standard Biochemical Autoantibodies
por: Yu, Liping, et al.
Publicado: (2012)

A New Approach for Diagnosing Type 1 Diabetes in Autoantibody-Positive Individuals Based on Prediction and Natural History
por: Sosenko, Jay M., et al.
Publicado: (2015)

Islet Autoantibody Seroconversion in the DPT-1 Study: Justification for repeat screening throughout childhood
por: Vehik, Kendra, et al.
Publicado: (2011)

The Metabolic Progression to Type 1 Diabetes as Indicated by Serial Oral Glucose Tolerance Testing in the Diabetes Prevention Trial–Type 1
por: Sosenko, Jay M., et al.
Publicado: (2012)

The Deterrence of Rapid Metabolic Decline Within 3 Months After Teplizumab Treatment in Individuals at High Risk for Type 1 Diabetes
por: Sims, Emily K., et al.
Publicado: (2021)

Progression to Diabetes in Relatives of Type 1 Diabetic Patients: Mechanisms and Mode of Onset
por: Ferrannini, Ele, et al.
Publicado: (2010)

Prognostic accuracy of inflammatory markers in predicting risk of ICU admission for COVID-19: application of time-dependent receiver operating characteristic curves
por: Geraili, Zahra, et al.
Publicado: (2022)

Fall in C-Peptide During First 2 Years From Diagnosis: Evidence of at Least Two Distinct Phases From Composite Type 1 Diabetes TrialNet Data
por: Greenbaum, Carla J., et al.
Publicado: (2012)

Feature ranking based on synergy networks to identify prognostic markers in DPT-1
por: Adl, Amin Ahmadi, et al.
Publicado: (2013)

Associations Between Serum Fatty Acids and Immunological Markers in Children Developing Islet Autoimmunity—The TRIGR Nested Case–Control Study
por: Niinistö, Sari, et al.
Publicado: (2022)

Performance of HbA(1c) as an Early Diagnostic Indicator of Type 1 Diabetes in Children and Youth
por: Vehik, Kendra, et al.
Publicado: (2012)

Slowed Metabolic Decline After 1 Year of Oral Insulin Treatment Among Individuals at High Risk for Type 1 Diabetes in the Diabetes Prevention Trial–Type 1 (DPT-1) and TrialNet Oral Insulin Prevention Trials
por: Sosenko, Jay M., et al.
Publicado: (2020)

Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association
por: Insel, Richard A., et al.
Publicado: (2015)

A novel method for interrogating receiver operating characteristic curves for assessing prognostic tests
por: Thomas, Grégoire, et al.
Publicado: (2017)

Distribution of C-Peptide and Its Determinants in North American Children at Risk for Type 1 Diabetes
por: Xu, Ping, et al.
Publicado: (2014)

Immunological and metabolic characteristics of the Omicron variants infection
por: Geng, Jiejie, et al.
Publicado: (2023)

Evaluation of an optimal receiver operating characteristic procedure
por: Jeffries, Neal, et al.
Publicado: (2009)

Analyzing receiver operating characteristic curves with SAS
por: Gönen, Mithat
Publicado: (2007)

Receiver operating characteristic analysis in medical imaging
por: International Commission on Radiation Units and Measurements. Bethesda
Publicado: (2008)

Receiver operating characteristic analysis: an ally in the pandemic
por: García, Jezreel Pantaleón, et al.
Publicado: (2021)

Diagnostic Accuracy of Chest Computed Tomography Scans for Suspected Patients With COVID-19: Receiver Operating Characteristic Curve Analysis
por: Wu, Lianpin, et al.
Publicado: (2020)

Receiver operating characteristic curve analysis in diagnostic accuracy studies: A guide to interpreting the area under the curve value
por: Çorbacıoğlu, Şeref Kerem, et al.
Publicado: (2023)

The clinical meaning of the area under a receiver operating characteristic curve for the evaluation of the performance of disease markers
por: Parodi, Stefano, et al.
Publicado: (2022)

Perspective Biological Markers for Autism Spectrum Disorders: Advantages of the Use of Receiver Operating Characteristic Curves in Evaluating Marker Sensitivity and Specificity
por: Abruzzo, Provvidenza M., et al.
Publicado: (2015)

The Compelling Case for Anti-CD3 in Type 1 Diabetes
por: Skyler, Jay S.
Publicado: (2013)

Immunological Characteristics of Patients Receiving Ultra-Short Treatment for Chronic Hepatitis C
por: Madsen, Lone Wulff, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6fmg6ekiijj06ghonbpo4td6rb